Vaccinex logo
Vaccinex Reports First Quarter 2022 Results and Provides Corporate Update
May 16, 2022 08:15 ET | Vaccinex, Inc.
Excellent Progress in Pepinemab Clinical Programs Promising responses in Phase 1b segment of the open-label KEYNOTE B84 study of pepinemab with KEYTRUDA® in Recurrent/Metastatic Head and Neck...
Picture1.png
Comprehensive Analysis in Frontiers in Neuroscience Highlights Acumen Pharmaceuticals’ New Approach to Treating Alzheimer's Disease
April 27, 2022 08:00 ET | Acumen Pharmaceuticals, Inc.
CHARLOTTESVILLE, Va. and CARMEL, Ind., April 27, 2022 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical stage biopharmaceutical company focused on the development of novel...
Future Market Insights.png
Alzheimer’s Therapeutics Market Is Set to Expand at a CAGR Of 9.3% To reach US$ 6.8 Bn By The Year 2032 : FMI DUBAI, United Arab Emirates, April 15, 2022 (GLOBE NEWSWIRE) -- Alzheimer’s Therapeutics is the most common reason for progressive dementia in the elderly population. There has been an exponential...
Logo Blue Main.png
Neuronascent Releases Further Positive Results of NNI-362 in A Randomized Phase 1a Trial for Alzheimer’s Disease
March 30, 2022 06:00 ET | Neuronascent, Inc.
ROCKVILLE, Md., March 30, 2022 (GLOBE NEWSWIRE) -- Neuronascent Inc., is a clinical-stage pharmaceutical company discovering and developing novel regenerative therapies for age-related brain...
Picture1.png
Acumen Pharmaceuticals Reports Financial Results for Full Year Ended December 31, 2021 and Business Highlights
March 28, 2022 16:05 ET | Acumen Pharmaceuticals, Inc.
Acumen is progressing ACU193, the first monoclonal antibody designed to selectively target toxic amyloid-beta oligomers (AβOs) to enter clinical testing Currently enrolling INTERCEPT-AD, a...
Picture1.png
Acumen Pharmaceuticals to Report Fourth Quarter and Full Year 2021 Financial Results on March 28, 2022
March 16, 2022 16:15 ET | Acumen Pharmaceuticals, Inc.
CHARLOTTESVILLE, Va. and CARMEL, Ind., March 16, 2022 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical stage biopharmaceutical company focused on the development of novel...
2020-0227 Cognition Logo for GNW.png
Cognition Therapeutics to Present Analyses from Clinical Studies of CT1812 in Patients with Alzheimer’s Disease at AD/PD 2022
March 10, 2022 07:30 ET | Cognition Therapeutics, Inc.
NEW YORK, March 10, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical stage neuroscience company developing drugs that treat age-related degenerative diseases of the...
CoreOneLabs_LOGO_COL_LRG_300dpi.png
Core One Labs’ Akome Biotech Initiates Neurogenesis Stimulation and Modeling Studies: Advancing its Proprietary Psychedelic-based Pharmaceutical Formulations
March 04, 2022 03:00 ET | Core One Labs Inc.
VANCOUVER, British Columbia, March 04, 2022 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD6, WKN: A3CSSU) (the “Company” or “Core One”) is pleased to announce that...
Vaccinex logo
Vaccinex Announces $6.6 Million Private Placement
January 27, 2022 16:15 ET | Vaccinex, Inc.
Participants include a syndicate of existing and new shareholdersContributes to total of $10.1 million in new equity financing for January, 2022 ROCHESTER, N.Y., Jan. 27, 2022 (GLOBE NEWSWIRE) --...
CoreOneLabs_LOGO_COL_LRG_300dpi.png
Core One Labs’ Akome Biotech Signs Research Agreement with University of Barcelona, Faculty of Pharmacy and Food Sciences
January 26, 2022 02:55 ET | Core One Labs Inc.
VANCOUVER, British Columbia, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD6, WKN: A3CSSU) (the “Company” or “Core One”) is pleased to announce that...